ArticleJournal of pathology and translational medicine2015
Expression of c-MET in Invasive Meningioma.
Article in Journal of pathology and translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05425004 (A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis.Brain tumor pathology · 2021Pooled it
- Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.Neuro-oncology · 2017Pooled it
- Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors.Molecular and cellular biochemistry · 2024Review
- Review
- Nomogram based on MRI can preoperatively predict brain invasion in meningioma.Neurosurgical review · 2022Article
- The impact of brain invasion criteria on the incidence and distribution of WHO grade 1, 2, and 3 meningiomas.Neuro-oncology · 2022Article
- Clinical and pathological impact of an optimal assessment of brain invasion for grade 2 meningioma diagnosis: lessons from a series of 291 cases.Neurosurgical review · 2022Article
- The efficacy of preoperative MRI features in the diagnosis of meningioma WHO grade and brain invasion.Frontiers in oncology · 2022Article
- Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options.Brain tumor pathology · 2021Review
- Regression of Intracranial Meningiomas Following Treatment with Cabozantinib.Current oncology (Toronto, Ont.) · 2021Article
- Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection.Cancer research and treatment · 2019Article
- Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging.Oncotarget · 2018Article
- Alteration status and prognostic value of MET in head and neck squamous cell carcinoma.Journal of Cancer · 2016Article
- Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningiomas show high recurrence rates even after curative tumor removal. The invasiveness of meningiomas may contribute to their high recurrence rates. Recently, c-MET and hepatocyte growth factor (HGF) have been reported to be involved in cancer invasion.
methodsWe examined the immunohistochemical expression of c-MET and HGF in 100 cases of patients with meningiomas who have undergone complete tumor removal.
resultsc-MET(-High) and HGFHigh were found in 17% and 13% of meningiomas, respectively. Brain invasion was observed in 17.6% of c-MET(-High) meningiomas, but in only 2.4% of c-MET(-Low) meningiomas (p=.033). Bone/soft tissue invasion was observed in 23.5% of c-MET(-High) meningiomas and in 9.6% of c-MET(-Low) meningiomas (p=.119). HGF(-High) did not show statistical association with brain invasion or bone/soft tissue invasion. c-MET(-High) demonstrated shorter recurrence-free survival (RFS, 93.5±8.2 months vs 96.1±1.9 months); however, this difference was not statistically significant (p=.139). There was no association of HGF(-High) with RFS.
conclusionsThis study demonstrates that c- MET(-High) is associated with brain invasion of meningiomas, and that c-MET expression may be a useful predictive marker for meningioma recurrence. Patients with invasive meningiomas with high expressions of c-MET may be good candidates for targeted therapy using c-MET inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.